Source: Business Standard, Mar 11, 2019
Mumbai: The cold wave in the US may bring big business for domestic pharma firms. The cold conditions there have resulted in spike in flu cases. Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication (Oseltamivir) in the US market, are likely to benefit.
The flu medicine market doubled in 2017-18 from the 2016-17 levels. According to data from the US Center for Disease Control and Prevention, there have been 20.4 million to 23.6 million flu illnesses in the US between October 1, 2018, and February 23, 2019. This caused 16,400 to 26,700 deaths there.
Natco, which launched its generic version of Tamiflu in the US in December 2016, reported a decline in the drug’s sales in recent times. After the third quarter results, Natco indicated that the decline in profits during the quarter was mainly due to margin reduction in its product Oseltamivir in the US. Tamiflu is a Roche brand. Its capsule version (an estimated $500-million market) has seven generics and the suspension (an estimated $250-million market) has four generics. Read the rest of this entry »